Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
Press releases
March 10, 2022
GelMEDIX
This partnership represents the first equity investment of the incubator created by HTL to accelerate the development of innovative treatments using biopolymers in therapeutic areas with unmet medical needs.
HTL will provide financial, industrial and scientific support to GelMEDIX to facilitate the development of next generation ocular and regenerative therapies based on its proprietary hydrogel platform.
This platform enables the delivery of therapeutics from small molecules to cell and gene therapies.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Articles April 2, 2025François Fournier Featured in Korean Press
HTL Biotechnology CEO François Fournier spoke to leading Korean media DongA Ilbo, reaffirming Korea’s strategic importance and the strong, long-standing ties with Korean customers.
-
Articles March 28, 2025HTL Biotechnology at AMWC Monaco 2025
We are excited to share that HTL Biotechnology is present at the AMWC 2025 in Monaco.
-
Articles March 11, 2025HTL Biotechnology at CIBE China
On March 10 to 12, 2025, HTL Biotechnology was proud to be present at CIBE (China International Beauty Expo) in Guangzhou, reaffirming our commitment to the dermatology and beauty industries.